People

Figures converted from DKK/EUR at historical FX rates — see data/company.json.fx_rates. Ratios, margins, and multiples are unitless and unchanged.

The People Running Novonesis

Governance grade: B. The combined company has a credible CEO, a clear controlling shareholder aligned with long-term science-driven stewardship (the Novo Nordisk Foundation), and a Danish-standard board. But a dual-class structure concentrates 63% of votes in 26% of capital, CEO pay roughly doubled to $7.1M in the merger year (top-5 in the C25), and the board includes several non-independent Novo Holdings nominees. Alignment is strong at the principal-shareholder level, weaker at the individual-executive level.

Governance Grade

Novo Holdings Votes

63.5%

Novo Holdings Capital

25.5%

1. The People Running This Company

Novonesis is run by a 10-person Executive Leadership Team dominated by ex-Novozymes leaders (roughly two thirds of the ExLT), with CEO Ester Baiget as the unifying figure. Only a handful of roles actually drive investor-relevant decisions.

No Results

Ester Baiget (CEO, since Feb 2020). Spanish chemical engineer who spent 25 years at Dow, rising to Business President of Dow's Industrial Solutions unit before being recruited to run Novozymes. She has now led the company through the most consequential event in its history — the Chr. Hansen merger — and delivered pro-forma organic growth of 8% and an adjusted EBITDA margin of 36.1% in year one, at the top of the initial guided range. Awards (PwC "Danish Business Leader of the Year 2024", Forbes Sustainability Leaders) and a Vice-Chair role at The B Team signal an external profile unusual for a Danish industrial CEO. Execution risk for the investor thesis is tied tightly to her continuation through the synergy run-rate period (through 2026).

Rainer Lehmann (CFO, since Nov 2023). Joined from Sartorius, where he was CFO for six years during its transformation into a global bioprocessing leader. His installation just before the merger close — replacing long-standing Novozymes CFO Lars Green — gave Novonesis a finance chief without legacy allegiances to either merger partner. Useful for neutral integration, but still early in tenure (operating through his first full post-merger cycle).

Cees de Jong (Chair, since 2024). Former CEO of Chr. Hansen and DSM Pharma Products; currently also Vice Chair of Novo Nordisk and Chair of Oterra (the lactase/colors business divested during the merger). Deep ingredient-biotech experience. The multi-hat Novo Group chair exposure (Novonesis, Novo Nordisk, Oterra) is a real governance flag — see Section 4.

**Integration note:** Ex-Novozymes personnel fill roughly two thirds of the ExLT while ex-Chr. Hansen leaders own the key customer-facing Food & Beverage and Human Health divisions. The split looks tilted but the P&L carriers of the Chr. Hansen franchise are run by Chr. Hansen veterans. The bigger risk is below the ExLT, where cultural integration is still in year two of a three-year synergy plan.

2. What They Get Paid

CEO total remuneration roughly doubled in 2024 on merger completion — from around $3.9M in the Novozymes years to $7.1M in the first Novonesis year, making Baiget the second-highest-paid C25 CEO by Finans's ranking and the fourth highest by Wikipedia's subsequent tally. On a company now roughly twice the size of pre-merger Novozymes, the step-up is defensible, but the pace and magnitude are aggressive relative to Danish norms.

Is it earned? Shareholders got 8% organic growth, 230bps of margin expansion, dividend maintained at $0.86 for the year, and a $104M buyback launched for 2025 — a strong first merger year. But the structure — roughly 45% long-term equity, 20–25% STI, 30% fixed + pension — puts most of the gain in share-linked comp, which benefited from the merger-completion re-rating more than from operating delivery alone. For comparison, the company targets long-run organic growth of 6–8% and EBITDA margin 37–38%. Meeting those is the bar that justifies pay at this level persisting past 2024.

**Watch item — 2025 remuneration report:** Because 2024 pay was merger-inflated, the 2025 remuneration report (AGM April 2026) will be the first "clean" post-integration read. A second consecutive year above $7.0M without a commensurate operational step-up would be a legitimate say-on-pay issue.

3. Are They Aligned?

Ownership and control

No Results

Novonesis has two share classes: A-shares (10 votes) and B-shares (1 vote). Novo Holdings, a wholly-owned subsidiary of the Novo Nordisk Foundation, owns all A-shares plus some B-shares — 25.5% of capital but 63.35% of votes. The Foundation's articles require it to always hold at least 25.5% of capital and a majority of the votes. In practice, activist intervention or hostile takeover is impossible without Foundation assent.

**The Foundation is an unusual controlling shareholder.** The Novo Nordisk Foundation is an enterprise foundation — a self-governing entity with no owners, mandated to reinvest returns into scientific, humanitarian, and social causes. It has held Novozymes since the 2000 demerger from Novo Nordisk and has historically supported high R&D intensity (10–14% of sales), long-term capex, and a prudent capital policy. That is a very different principal from a family office or activist fund.

Insider buying and selling

No material open-market buying or selling by executives has been disclosed in the available Danish filings (Finanstilsynet flaggings) or via Simply Wall St's insider-trading feed for the 12 months since listing. The Danish regime requires prompt disclosure of manager transactions; the absence of sustained insider activity in either direction is normal for a controlled European company but means there is no "price-signal" from management behavior either way.

No Results

The only large issuance in recent years was the merger-consummation capital increase in January 2024: $9.4B nominal equity issued to Chr. Hansen shareholders in exchange for shares. That is a shareholder vote outcome, not a dilutive act. Ongoing LTIP grants are modest relative to the float. A $104M buyback for 2025 signals that dilution is not a concern for management.

The Novo Holdings relationship is the main related-party lens. Three links to watch:

Chair Cees de Jong also chairs Oterra (Chr. Hansen's lactase-color unit divested during the merger to an EQT-controlled vehicle) — a legitimate capability link but a latent conflict on any future dealings.
Kasim Kutay sits on the Novonesis board as CEO of Novo Holdings and is simultaneously on the Novo Nordisk board. Capital allocation at one Novo Group company is visible to the other.
The Feed Enzyme Alliance wind-down with dsm-firmenich ($1.56B cash consideration announced Feb 2025) is an arm's-length transaction with an unrelated counterparty — not a related-party concern.

No disclosed related-party transactions of concern between Novonesis and Novo Holdings in 2024. Management compensation, advisory fees, and service contracts are disclosed in line with Danish Corporate Governance Code.

Capital allocation behavior

No Results

Policy is a 40–60% dividend payout plus opportunistic buybacks once leverage targets are met. NIBD/EBITDA was 1.4x at end 2024 — deleveraging from the merger remains the priority, constraining buyback size. The Feed Enzyme Alliance buyout at $1.56B is a logical portfolio move but tests capital discipline; investors should watch the return on that capital through 2026–2027.

Skin-in-the-game score

Skin in the Game (1–10)

7/10. The Foundation's perpetual 25.5%+ holding is the strongest possible "skin" a public company can have: the controlling shareholder is structurally unable to sell. Executive ownership is less impressive — CEO and CFO have moderate share positions through vested LTIP, but nothing disclosed at the level of "personal wealth concentrated in this stock." Score is dragged down from 9 to 7 by that asymmetry and by pay being weighted toward share-linked comp rather than required personal cash purchases.

4. Board Quality

No Results

No Results

Where the board is strong: Finance expertise is exceptional — an Audit Chair (Dalsgaard) who is a sitting C25 CFO, plus Brandgaard (ex-Novo Nordisk CFO) and Kaae (ex-Bestseller CFO). Scientific depth is adequate through Sommer (professor of biosustainability at DTU) and the operating experience of de Jong and Stratton. The committee structure matches Danish Corporate Governance Code.

Where it is weaker: Three of the nine directors (Kutay, Dalsgaard via Oterra, de Jong via Oterra and Novo Nordisk) have some form of Novo Group linkage. That is inherent to the ownership structure — but in practice the independent directors must carry the weight of challenging both management and the controlling shareholder. The addition of Monila Kothari on a one-year term in April 2025 was the most recent refresh.

**Dominant-shareholder tension.** Every material strategic choice — synergy targets, dividend policy, Feed Enzyme Alliance acquisition, future bolt-ons — is ultimately endorsed by a board where the Foundation's representative is the single largest voting bloc and the Chair also serves in two other Novo Group roles. Minority investors are well-protected by Danish law and by the Foundation's own long-horizon incentive, but **they do not have the structural power to force a different course**.

5. The Verdict

Governance Grade

Grade: B.

Strongest positives

Foundation-anchored ownership provides the longest patience horizon available in public markets and has historically sustained industry-leading R&D intensity.
CEO has delivered — 8% organic growth and 36.1% EBITDA margin in year one of the most complex merger in European specialty chemicals since Syngenta.
Board has real financial and scientific expertise; independent majority; active refresh.
Capital policy is conservative and disclosed (40–60% payout, deleveraging then buyback).

Real concerns

Vote concentration. 26% of capital controls 63% of votes. Minority holders cannot force change. This is an accepted feature of Danish foundation-owned companies, but it should be priced in.
CEO pay step-up. $7.1M in 2024 is defensible given the doubling of company scale, but a repeat in 2025 without commensurate operational delivery would be a legitimate say-on-pay event.
Chair conflicts. Cees de Jong's three Novo Group roles (Novonesis Chair, Novo Nordisk Vice Chair, Oterra Chair) are a governance thinness point; replacement with a fully independent chair would be an upgrade.
Executive skin-in-the-game is moderate, not high. The Foundation carries the alignment burden.

The single item most likely to change the grade

Upgrade trigger: A separation of the Chair role from other Novo Group seats + a Novonesis-specific MSOP-style "pay-for-performance" framework where LTIP vesting is tied to 3-year ROIC/organic-growth gates rather than merger-year share price inflation. This would move the grade to B+/A-.
Downgrade trigger: Any related-party transaction with Oterra, Novo Nordisk, or a Novo Holdings portfolio company that is not obviously arm's-length; a second year of CEO pay above $7.0M without clear operational linkage; or an acquisition that materially impairs return on invested capital. Any one would push toward B-.